Navigation Links
SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
Date:3/21/2013

JERUSALEM, March 21, 2013 /PRNewswire/ --

SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of voice activated drug safety application announced today that the company is actively initiating a business development plan to commercialize its newly acquired technology.

During the first stage of the business development plan, SafeCode intends to initiate a formal search for market-tested executives to help the company's management team and to raise additional funds to reach its commercialization objectives.

The company recently reported that SafeCode Drug Technologies acquired Quickool and EZJect technology from Sindolor Medical Ltd., an Israel-based medical technologies development company.  The breakthrough Quickool technology enabling individuals to self-administer pain free injections.

The technologies enable individuals to safely and painlessly administer injections or blood lancing, by quickly cooling the site of the injection immediately prior to the piercing of the skin.  The technology is particularly useful for patients with diabetes who need to test blood-sugar levels or inject themselves regularly with insulin.  

Sindolor had previously been in involved in advanced negotiations with a major pharmaceutical company to fully commercialize the painless injection technology.

"The company is extremely optimistic that we can bring our newly acquired pain reduction technologies to market, in addition to the market-tested life-saving technologies that SafeCode already offers," said Joel Klopfer , Chief Executive Officer of SafeCode Drug Technologies.  "We are excited by the opportunities this technology presents to our shareholders, and we intend to keep providing updates on our business development activities."

About SafeCode Drug Technologies

SafeCode Drug Technologies is the developer of patent-pending technologies based on voice recognition for drug safety application.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
Joel Klopfer
Joel.Klofer1@gmail.com
+9722-5021322



'/>"/>
SOURCE Safecode Drug Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
2. SafeCode Drug Technologies Corp. in Negotiations With Manufacturers to Develop Prototype
3. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
4. SafeCode Drug Technologies Corporation Identifies the Technology Group to Commence and Develop the Worlds First Prototype for its Next Generation Application for Drug Safety Administration
5. SafeCode Drug Technologies Corp Signs an Agreement With INTOVISION PRODUCT DEVELOPMENT & DESIGN (An Israeli Product Development Co) to Manufacturers the Worlds First Voice Recognition Drug Safety Application Prototype
6. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
7. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
11. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Los innovadores ... del mundo, introduce catéteres para la intervención de ... una compañía global especializada en el suministro de ... su cartera incluyendo productos para tratar la enfermedad ... PTA son los dispositivos de primera entrada de ...
(Date:5/24/2016)... -- Een app die artsen over de ... kunnen behandelen, hun kennis kunnen delen en van elkaar ... en revolutionaire MDLinking App, ontwikkeld door een internationale groep ... Flu en oncologisch chirurg dr. Gijs van Acker ... op dinsdag 24 mei officieel gepresenteerd op het Amsterdam ...
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
Breaking Medicine Technology:
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene ... billion women around the world who do not have access to a toilet, even when ... about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on the ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria Health Announces ... Begin In June , Aloria Health, specializing in a re-imagined, client-oriented approach to ... Milwaukee, its first treatment facility for outpatient, day treatment and residential care. Aloria ...
(Date:5/24/2016)... ... May 24, 2016 , ... Global ... and education, today announced that it has named Scott Santarella as its new ... Addario Lung Cancer Foundation (ALCF) in San Francisco, where he successfully helped to ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Dignity Health has ... month. The new facility is licensed under Dignity Health Arizona General Hospital, which ... of Dignity Health in Arizona, said that the new facility will complement Dignity Health’s ...
Breaking Medicine News(10 mins):